While equity styles go in and out of favor, high-quality equities have proven to be a stable group of exceptional businesses ideally suited to compounding capital and resilient to market drawdowns.
In 2004, GMO launched the Quality Strategy with the mandate to own attractively valued stocks within the quality universe. The creation of the strategy was the culmination of decades of GMO research on quality business models. While the strategy’s origins date back to GMO’s earliest days, our process continues to evolve to ensure sustained relevance as well as our investment edge.
The GMO Quality Strategy is an ideal core equity holding that has delivered strong returns, stability, and risk mitigation for investors for 20 years and counting. In recent years, we’ve successfully extended our differentiated approach to other universes, including defensive equity/absolute return, small caps, and global value.
Suite of GMO Quality Strategies
Small Cap Quality
Flagship long-only strategy; global or U.S. domiciles; seeks to deliver superior return at lower volatility than the broader market
Enhance the risk mitigation by balancing quality with a “junk” short ~175/75
Exploit the superior outperformance of quality stocks within small caps
The highest quality cyclicals have strong fundamentals across the cycle, yet are discounted for short-term volatility
|Defensive equity, absolute return
|U.S. small cap
S&P 500, MSCI World
50% MSCI ACWI/50% Cash, MSCI ACWI
|S&P 600 or other small cap index
Number of Positions
|40-50 long, 300+ short
U.S. Quality Strategy
GMO’s Focused Equity team now offers a U.S.–focused version of its flagship Quality Strategy, offering investors access to the strong and diversified quality opportunity set in the U.S. without the scarcity premium that often accompanies non-U.S. quality equities.
Learn about the recently launched GMO U.S. Quality Strategy.
Small Cap Quality Strategy
We launched the GMO Small Cap Quality Strategy in 2022, convinced it was an opportune moment to capitalize on our approach as the long-term advantages of quality investing in small caps had aligned with unusually attractive small cap quality valuations. One year later, we’re pleased to report that our results exceeded even our most optimistic projections.
Read about our first year with the GMO Small Cap Quality Strategy